Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice

British Journal of Pharmacology

Volumn 154, Issue 4, 2008, Pages 812-824

  Islam, M S ^a   Murata, T ^a   Fujisawa, M ^a   Nagasaka, R ^b   Ushio, H ^b   Bari, A M ^a   Hori, M ^a   Ozaki, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF MARINE SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

oryzanol; Antioxidant; Colitis; Cycloartenyl ferulate; NF B; Phytosteryl ferulates; Pro inflammatory cytokines

Indexed keywords

24 METHYLENECYCLOARTANYL FERULATE; BETA SITOSTERYL FERULATE; CAMPESTERYL FERULATE; CYCLOARTENYL FERULATE; CYCLOOXYGENASE 2; CYTOKINE; DEXTRAN SULFATE; FERULIC ACID; GAMMA ORYZANOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; PHYTOSTEROL; PHYTOSTERYL FERULATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; COLITIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MACROPHAGE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RICE BRAN; RNA EXTRACTION; WESTERN BLOTTING;

ALPHA-TOCOPHEROL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; COLITIS; COUMARIC ACIDS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; ORYZA SATIVA; PHENYLPROPIONATES; PHYTOSTEROLS;

EID: 44949119375     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.137     Document Type: Article

References (55)

1. Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R (2006). Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther 318: 68-78.
2. Ardizzone S, Bianchi Porro G (2005). Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286.
3. Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P (2004). Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 59: 304-314.
4. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D et al. (1999). Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28.
5. Baldwin Jr AS (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
6. Bharti AC, Donato N, Singh S, Aggarwal BB (2003). Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062.
7. Bligh EG, Dyer WJ (1959). A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
8. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P et al. (1994). Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
9. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V et al. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333-342.
10. D'Angio CT, Finkelstein JN (2000). Oxygen regulation of gene expression: a study in opposites. Mol Genet Metab 71: 371-380.
11. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F et al. (1999). Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116: 1029-1034.
12. Domenech E (2006). Inflammatory bowel disease: current therapeutic options. Digestion 73 (Suppl 1): 67-76.
13. Dong WG, Liu SP, Yu BP, Wu DF, Luo HS, Yu JP (2003). Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J Gastroenterol 9: 2533-2538.
14. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS et al. (1996). Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 157: 2174-2185.
15. Gonzalez-Rey E, Chorny A, Delgado M (2006). Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130: 1707-1720.
16. Hanauer SB (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 (Suppl 1): S3-S9.
17. Hanauer SB, Present DH (2003). The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3: 81-92.
18. Hiramitsu T, Armstrong D (1991). Preventive effect of antioxidants on lipid peroxidation in the retina. Ophthalmic Res 23: 196-203.
19. Jagetia GC, Aggarwal BB (2007). 'Spicing up' of the immune system by curcumin. J Clin Immunol 27: 19-35.
20. Jariwalla RJ (2001). Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res 27: 17-26.
21. Jiang H, Deng CS, Zhang M, Xia J (2006). Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12: 3848-3853.
22. Juliano C, Cossu M, Alamanni MC, Piu L (2005). Antioxidant activity of gamma-oryzanol: mechanism of action and its effect on oxidative stability of pharmaceutical oils. Int J Pharm 299: 146-154.
23. Jurjus AR, Khoury NN, Reimund JM (2004). Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 50: 81-92.
24. Kamata H, Hirata H (1999). Redox regulation of cellular signalling. Cell Signal 11: 1-14.
25. Kim SJ, Han D, Moon KD, Rhee JS (1995). Measurement of superoxide dismutase-like activity of natural antioxidants. Biosci Biotechnol Biochem 59: 822-826.
26. Kinoshita K, Hori M, Fujisawa M, Sato K, Ohama T, Momotani E et al. (2006). Role of TNF-alpha in muscularis inflammation and motility disorder in a TNBS-induced colitis model: clues from TNF-alpha-deficient mice. Neurogastroenterol Motil 18: 578-588.
27. Kurtovic J, Segal I (2004). Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 25: 9-14.
28. Kwon HS, Oh SM, Kim JK (2008). Glabridin, a functional compound of liquorice, attenuates colonic inflammation in mice with dextran sulphate sodium-induced colitis. Clin Exp Immunol 151: 165-173.
29. Li Q, Verma IM (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
30. Lin CM, Chen CT, Lee HH, Lin JK (2002). Prevention of cellular ROS damage by isovitexin and related flavonoids. Planta Med 68: 365-367.
31. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006). Multiple biological activities of curcumin: a short review. Life Sci 78: 2081-2087.
32. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA (2006). The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147: 873-885.
33. May MJ, Ghosh S (1998). Signal transduction through NF-kappa B. Immunol Today 19: 80-88.
34. Mayer EA, Collins SM (2002). Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122: 2032-2048.
35. Melgar S, Karlsson A, Michaelsson E (2005). Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288: G1328-G1338.
36. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F (2002). Immunoregulation in the gut: success and failures in human disease. Gut 50 (Suppl 3): III60-III64.
37. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993). Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709.
38. Na HK, Surh YJ (2006). Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol Nutr Food Res 50: 152-159.
39. Nagasaka R, Chotimarkorn C, Shafiqul IM, Hori M, Ozaki H, Ushio H (2007). Anti-inflammatory effects of hydroxycinnamic acid derivatives. Biochem Biophys Res Commun 358: 615-619.
40. Ohda Y, Hori K, Tomita T, Hida N, Kosaka T, Fukuda Y et al. (2005). Effects of hepatocyte growth factor on rat inflammatory bowel disease models. Dig Dis Sci 50: 914-921.
41. Panwala CM, Jones JC, Viney JL (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161: 5733-5744.
42. Papadakis KA, Targan SR (2000). Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298.
43. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J et al. (2002). Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33: 311-322.
44. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D et al. (1997). A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159: 6276-6282.
45. Podolsky DK (2002). Inflammatory bowel disease. N Engl J Med 347: 417-429.
46. Podolsky DK (2003). The future of IBD treatment. J Gastroenterol 38 (Suppl 15): 63-66.
47. Reifen R, Nissenkorn A, Matas Z, Bujanover Y (2004). 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J Gastroenterol 39: 514-519.
48. Rojas-Cartagena C, Flores I, Appleyard CB (2005). Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 32: 85-93.
49. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R et al. (2007). The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis. J Immunol 178: 8138-8147.
50. Strober W, Fuss IJ, Blumberg RS (2002). The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549.
51. Surh Y (1999). Molecular mechanisms of chemopreventive effects of selected dietary andmedicinal phenolic substances. Mutat Res 428: 305-327.
52. Tak PP, Firestein GS (2001). NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
53. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. (1995). Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
54. Xu Z, Godber JS (1999). Purification and identification of components of gamma-oryzanol in rice bran Oil. J Agric Food Chem 47: 2724-2728.
55. Xu Z, Hua N, Godber JS (2001). Antioxidant activity of tocopherols, tocotrienols, and gamma-oryzanol components from rice bran against cholesterol oxidation accelerated by 2, 2′-azobis(2-methylpropionamidine) dihydrochloride. J Agric Food Chem 49: 2077-2081.